HealthRX.com · Printable missed-dose plan
Sermorelin missed or doubled dose record for the pharmacist or prescriber
Copy the product details from the vial and dispensing label, write down exactly what happened, then call the dispensing pharmacist or prescriber and record their answer. It keeps the urgent-help signs and the regulatory background on the same sheet.
The product, copied from the vial and label
Dispensing pharmacy and exact product name
Concentration printed on the vial
Amount written on the dispensing label
Prescribed frequency and your usual time
Missed-dose wording on the label, if anycopy it word for word
What happened
Last dose you are sure of: date and time
Missed, or possibly taken twice?
Symptoms now
Other medicines and medical conditions
Storage problemsleft out of the fridge, frozen, travel
Do not wait for a callback if
- Someone collapses, has a seizure, has trouble breathing or cannot be woken: call 911.[1]
- A possible double dose or unexpected symptoms: Poison Control at 1-800-222-1222 gives case-specific advice.[1]
Background to check the advice against
- Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed.[2]
- FDA withdrew approval of both Geref sermorelin products effective June 18, 2009, so no current approved label carries missed-dose directions.[3]
- FDA's notice of 03/04/2013 found Geref was not withdrawn from sale for reasons of safety or effectiveness.[3]
- The Geref pediatric trial treated children with growth hormone deficiency for up to 1 year; it was not a study of missed doses.[4]
The answer you were given
Who you spoke to, and when
What to do about this dose
When the next dose is due
Can the label be updated with a missed-dose instruction?
Sources for the facts on this sheet
- National Capital Poison Center. First aid: Act fast! | Poison Control. Accessed 2026-10-18. https://www.poison.org/first-aid-for-poisonings
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed 2026-10-18. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration, Federal Register. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Accessed 2026-10-18. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
- Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab 1996. PMID 8772599. https://pubmed.ncbi.nlm.nih.gov/8772599/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.